Developed by Ireland-based BrePco Biopharma, Neoatricon is the first paediatric-strength dopamine hydrochloride infusion for ...

dopamine should be initiated or, if currently administered, the dose should be increased. The goal of the treatment of hypotension/shock is to attain cardiovascular stability as soon as possible.

Piramal Critical Care has reserved commercialisation rights for the EU, UK, and Norway and will look after Neoatricon in ...

Dublin: BrePco Biopharma Limited (BPCO) that develops products for the unique needs of paediatric patients and Piramal ...